Page 489 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C4.2. Comparison between watchful waiting and radical prostatectomy (continued)
Author, Year Study name Comparison Outcome Followup Sample size Results Factors included in the
[Pubmed ID] /Database definition/ (yr) per group model
measurement
Study design instrument
Stattin 223 NPCRSFS RP vs. Death from Median Surveillance: HR=0.49 (0.34, 0.71) Age at diagnosis,
2010 surveillance prostate cancer followup 2021 comorbidity,
20562373 as “underlying 8.2 yr RP: 3399 socioeconomic group,
cause of (IQR=7.1- risk group.
Retrospective death,” data 9.7 yr)
cohort obtained from
the Cause of
Death Register
or review of
death
certificates
Albertsen 209 Connecticut RP vs. no initial Prostate cancer Median WW: 114 HR=0.29 (0.17, 0.52) Stratification by D’Amico
2007 Tumor treatment death; dates followup RP: 802 risk category, Gleason
17296379 Registry and causes of 13.3 yr intended (596 score, PSA, clinical
death were (IQR=12.8- received) stage, age at diagnosis,
Retrospective obtained from 13.9 yr) and Charlson
cohort the Connecticut comorbidity score
Tumor Registry [Gleason score values
were based on a
contemporary (2003) re-
grading of the pathology
slides]
All-cause
mortality
Bill-Axelson 213 SPCG-4 RP vs. WW Overall 12.8 RP: 347 RR=0.75 (0.61, 0.92); None (RCT)
2011 mortality WW: 348 P=0.007
21542742

RCT
Schymura 230 POCS CDC- RP vs. WW 5-year survival 5 years RP: 1321 HR=0.43 (0.32, 0.59) Age at diagnosis,
2010 NPCR WW: 619 race/ethnicity, marital
20403178 status, registry location,
PSA value, Gleason
Retrospective score, comorbidity score
cohort

C-162